DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Release Order - Certificate No. RC7376 of 2023 in respect of Padam Prabhu Vanijya Pvt Ltd (PAN: AAECP9720F) in the matter of Illiquid Stock Options

SEBI 1 hr ago·14 Sept 2026, 12:34 pm

Company SEBI

The Securities and Exchange Board of India (SEBI) has issued a release order regarding the illiquid stock options of Padam Prabhu Vanijya Pvt Ltd. This order pertains to a specific regulatory certificate, RC7376 of 2023, which outlines the regulator's decision in this matter. The order is a formal communication from SEBI and does not necessarily indicate a violation by the company itself.

This development is primarily of interest to investors who hold or are tracking the illiquid stock options of this specific entity. For the broader market, this serves as a reminder of SEBI's ongoing efforts to monitor and regulate the trading of less liquid securities. It highlights the importance of understanding the risks associated with such instruments.

Investors should monitor further updates from SEBI or the company for any additional details or implications. The order itself is a regulatory action, and its direct impact on the stock's price or liquidity will depend on the specific circumstances outlined in the full release.